查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138141

3D生物列印和組織工程市場預測至2034年—按技術、材料、應用、最終用戶和地區分類的全球分析

3D Bioprinting & Tissue Engineering Market Forecasts to 2034 - Global Analysis By Technology, Material, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球 3D 生物列印和組織工程市場規模將達到 29 億美元，並在預測期內以 19.8% 的複合年成長率成長，到 2034 年將達到 124 億美元。

3D生物列印和組織工程結合了生物列印技術、活細胞、生物材料和生物組件，用於開發再生醫學和治療用途的人工組織。這使得建構個人化結構成為可能，這些結構旨在模擬天然組織環境，促進細胞生長和再生。生物墨水配方、細胞列印、支架設計和數位建模方面的進步正在提高製造精度和組織功能。主要應用領域包括皮膚、骨骼、軟骨、血管和器官相關組織的開發，研究目標是建立日益複雜的結構並提高組織完整性。

根據美國國立衛生研究院 (NIH) 下屬的國家轉化科學促進中心 (NCATS) 的報告，約 90% 的新藥在臨床試驗中失敗，因為傳統的實驗室和動物模型可能無法準確預測人體反應。因此，NIH 正在利用 3D 生物列印技術創建組織模型，以改善藥物篩檢和研發。

對再生醫學的需求日益成長

隨著醫學研究人員探索修復受損或病變組織的技術，再生醫學的日益普及正在推動市場發展。 3D生物列印技術利用活細胞、生物材料和特殊生物墨水，建構患者特異性的客製化生物結構，為骨再生、軟骨重組、傷口護理和組織替代等領域提供了應用前景。個人化醫療方法的拓展正在推動技術進步和研究活動。因此，生物製造、支架開發、細胞工程和組織構建等領域的創新正在促進生物列印技術在醫學領域的應用。

3D生物列印系統高成本

高昂的生物列印設備、專用生物墨水、配套設施以及持續的維護成本是市場擴張的主要障礙。現代3D生物列印系統通常需要先進的硬體、專用軟體、受控的實驗室環境和熟練的人員，導致前期投入和營運成本龐大。開發、測試和檢驗合適的生物材料也會產生額外的費用，進一步加重預算負擔。因此，這些技術難以實施，尤其對於資金籌措有限、缺乏先進生物醫學研究和基礎設施的小規模研究機構和醫療機構而言更是如此。

個性化組織工程的擴展

隨著個人化組織工程的日益普及，生物列印技術能夠建構滿足個別患者需求的客製化結構，從而創造了市場發展機會。客製化設計可以整合特定的解剖結構特徵、生物材料和細胞成分，顯著提升其在再生醫學和重組醫學領域的應用潛力。人們對個人化醫療解決方案的日益關注，推動了針對患者特異性支架、植入和組織模型的研究。醫學影像、計算設計和細胞技術的進步有望進一步增強客製化能力，並拓展生物列印在臨床應用中的範圍。

倫理和生物安全問題

倫理考量和生物安全風險可能對3D生物列印和組織工程市場的發展構成挑戰。涉及活細胞、遺傳成分和人工組織的技術需要對其安全性和潛在的長期影響進行仔細評估。細胞取得、生物材料改造、人工組織所有權以及技術濫用的可能性等問題可能會引起監管機構的關注，並影響技術的接受度。對長期後果缺乏了解可能會延緩其在臨床環境中的廣泛應用。因此，嚴格的安全標準、倫理指南和透明的調查流程對於技術的持續發展至關重要。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為3D生物列印和組織工程市場帶來了挑戰和機會。初期，實驗室暫時關閉、供應鏈中斷、臨床研究受限、資金籌措短缺等問題導致技術研發和投資放緩。另一方面，疫情也激發了人們對生物醫學研究、快速生產技術、疾病建模和藥物測試的濃厚興趣。生物列印作為一種建構與新冠病毒研究相關的生物模型的方法，吸引了研究人員的注意。隨著研究機構的重新開放，研發項目和投資活動逐漸恢復，推動了市場復甦。

在預測期內，擠出式生物列印領域預計將佔據最大的市場佔有率。

由於擠出式生物列印技術具有柔軟性、與多種材料相容以及適用於製造包括細胞和生物材料在內的各種結構等優點，預計在預測期內，該技術將佔據最大的市場佔有率。這種方法允許研究人員透過噴嘴逐層精確沉積生物墨水，從而建立客製化的組織結構和支架。其能夠處理各種材料黏度、操作簡單且適應不同的生物設計，使其成為極為有用的科學研究技術。該技術可應用於組織工程、再生醫學、疾病建模、藥物研發以及其他生物醫學開發活動。

在預測期內，美容診所細分市場預計將呈現最高的複合年成長率。

在預測期內，隨著對創新美容和重組解決方案的需求不斷成長，美容診所領域預計將呈現最高的成長率。生物列印技術可用於個人化組織結構、皮膚替代品、植入和再生醫學等領域，旨在滿足個人化需求。人們對客製化美容手術日益成長的興趣，以及生物製造技術的進步，正在為診所拓展商機。此外，人工皮膚和組織再生技術的不斷發展也推動了生物列印技術在美容、美學和重組治療領域的應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的生物技術基礎設施、完善的研究網路以及活躍的再生醫學活動。大學、製藥公司、生技公司和醫療機構在尖端生物列印研發領域的合作日益密切。該地區的創新環境有利於生物墨水、組織模型、生物列印平台和人工生物結構等領域的進步。政府和私人部門對生物醫學技術的持續投資也推動了創新和商業化進程，進一步鞏固了北美在全球生物列印和組織工程領域的重要角色。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健體系的發展、研究活動的拓展以及對再生醫學投資的增加。中國、日本、韓國和印度正透過技術創新、機構研究以及產學研合作推動生物列印技術的發展。人們對個人化醫療解決方案日益成長的興趣也促進了這項技術的應用。生物製造技術的進步、生物技術和製藥行業的擴張以及政府主導的研究舉措，都為該地區生物列印技術的持續發展創造了有利條件。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算、預測和複合年成長率計算（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球3D生物列印與組織工程市場：依技術分類

  • 擠出式生物列印
  • 噴墨列印和生物列印
  • 雷射輔助生物列印
  • 磁性生物列印
  • 光聚合

第6章 全球3D生物列印與組織工程市場：依材料分類

  • 天然生物材料
  • 合成生物材料
  • 混合生物材料
  • 活細胞

第7章 全球3D生物列印與組織工程市場：依應用領域分類

  • 組織工程
  • 器官移植與再生
  • 藥物發現與開發
  • 美容重組手術
  • 癌症研究模型

第8章 全球3D生物列印與組織工程市場：依最終用戶分類

  • 學術研究機構
  • 製藥和生物技術公司
  • 醫院和外科中心
  • 美容診所

第9章 全球3D生物列印與組織工程市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • 3D Systems Inc.
  • Advanced Solutions Life Sciences LLC
  • Aspect Biosystems Ltd.
  • Cellbricks
  • Clecell
  • CollPlant Biotechnologies Ltd.
  • CTIBIOTECH（TM）
  • Cyfuse Biomedical KK
  • Inventia Life Science Pty Ltd.
  • GeSiM-Gesellschaft fur Silizium-Mikrosysteme mbH
  • Integra LifeSciences Corporation
  • Materialise
  • Organovo Holdings Inc.
  • Poietis
  • RegenHU
  • Stratasys Ltd.
  • TissueLabs
  • Regemat 3D
Product Code: SMRC39744

According to Stratistics MRC, the Global 3D Bioprinting & Tissue Engineering Market is accounted for $2.9 billion in 2026 and is expected to reach $12.4 billion by 2034 growing at a CAGR of 19.8% during the forecast period. 3D Bioprinting & Tissue Engineering combines bioprinting techniques, living cells, biomaterials, and biological components to develop engineered tissues for regenerative and therapeutic purposes. It enables the production of personalized structures designed to imitate natural tissue environments and encourage cell growth and regeneration. Progress in bioink formulations, cellular printing, scaffold design, and digital modeling is enhancing manufacturing accuracy and tissue functionality. Key applications include skin, bone, cartilage, vascular, and organ-related tissue development, with research increasingly targeting complex structures and improved tissue integration.

According to the U.S. National Institutes of Health (NIH), it's National Center for Advancing Translational Sciences (NCATS) reports that about 90% of potential new drugs fail in clinical trials because traditional laboratory and animal models may not accurately predict human responses. NIH is therefore using 3D bioprinted tissue models to improve drug screening and development.

Market Dynamics:

Driver:

Rising demand for regenerative medicine

Increasing interest in regenerative medicine is supporting market development as healthcare researchers seek technologies capable of restoring injured or diseased tissues. 3D bioprinting provides techniques for producing customized biological structures from living cells, biomaterials, and specialized bioinks, creating opportunities for applications such as bone regeneration, cartilage reconstruction, wound treatment, and tissue replacement. The expansion of personalized therapeutic approaches is encouraging technological advancement and research activities. Consequently, innovations in biofabrication, scaffold development, cellular engineering, and tissue construction are strengthening the use of bioprinting in healthcare.

Restraint:

High cost of 3D bioprinting systems

Expensive bioprinting equipment, specialized bioinks, supporting facilities, and ongoing maintenance represent significant barriers to market expansion. Modern 3D bioprinting systems often require advanced hardware, specialized software, controlled laboratory conditions, and trained personnel, resulting in substantial initial and operating expenditures. Additional costs related to developing, testing, and validating appropriate biomaterials can place further pressure on budgets. Consequently, smaller research organizations and healthcare facilities may experience difficulties adopting these technologies, especially when access to funding for sophisticated biomedical research and infrastructure is limited.

Opportunity:

Expansion of personalized tissue engineering

Growing adoption of personalized tissue engineering creates opportunities for market development as bioprinting technologies enable the fabrication of structures tailored to individual patient requirements. Customized designs can incorporate specific anatomical characteristics, biomaterials, and cellular components, supporting potential applications in regenerative and reconstructive medicine. Rising interest in individualized healthcare solutions is stimulating research into patient-specific scaffolds, implants, and tissue models. Improvements in medical imaging, computational design, and cell technologies can further enhance customization capabilities and broaden the use of bioprinting across clinical applications.

Threat:

Ethical and biosafety concerns

Ethical considerations and biosafety risks may create challenges for the development of the 3D Bioprinting & Tissue Engineering Market. Technologies involving living cells, genetic components, and engineered tissues require careful assessment of safety and potential long-term consequences. Issues related to sourcing cells, modifying biological materials, ownership of engineered tissues, and possible technological misuse can increase regulatory attention and affect acceptance. Limited understanding of long-term outcomes may delay broader clinical implementation. Strong safety standards, ethical guidelines, and transparent research processes are therefore essential for continued advancement.

Covid-19 Impact:

COVID-19 created both challenges and opportunities for the 3D Bioprinting & Tissue Engineering Market. Early disruptions included temporary laboratory shutdowns, interrupted supply chains, limited clinical research, and funding constraints that slowed technology development and investment. At the same time, the pandemic encouraged greater attention toward biomedical research, rapid production technologies, disease modeling, and pharmaceutical testing. Bioprinting gained research interest for creating biological models relevant to COVID-19 studies. With research facilities reopening, development programs and investment activities progressively resumed, strengthening market recovery.

The extrusion-based bioprinting segment is expected to be the largest during the forecast period

The extrusion-based bioprinting segment is expected to account for the largest market share during the forecast period because of its flexibility, broad material compatibility, and suitability for producing structures containing cells and biomaterials. The method precisely deposits bioinks through a nozzle in successive layers, allowing researchers to construct customized tissue architectures and scaffolds. Its ability to accommodate different material viscosities, practical operating approach, and adaptability to varied biological designs make it valuable for research. The technology supports applications in tissue engineering, regenerative medicine, disease modeling, pharmaceutical studies, and other biomedical development activities.

The cosmetic clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cosmetic clinics segment is predicted to witness the highest growth rate as demand for innovative aesthetic and reconstructive solutions increases. Bioprinting technologies can support personalized tissue structures, skin substitutes, implants, and regenerative applications designed around individual needs. Greater interest in customized cosmetic procedures, combined with improvements in biofabrication, is expanding opportunities for clinics. Ongoing development of engineered skin and tissue regeneration techniques is also encouraging the adoption of bioprinting technologies across cosmetic, aesthetic, and reconstructive treatment applications.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by sophisticated biotechnology infrastructure, established research networks, and strong regenerative medicine activities. Universities, pharmaceutical companies, biotechnology firms, and healthcare organizations increasingly collaborate on advanced bioprinting research and development. The region's innovation environment supports progress in bioinks, tissue models, bioprinting platforms, and engineered biological structures. Continued government and private investment in biomedical technologies also encourages innovation and commercialization, reinforcing North America's significant role in the global bioprinting and tissue engineering landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by developing healthcare systems, expanding research activities, and greater investment in regenerative medicine. China, Japan, South Korea, and India are advancing bio printing through technological innovation, institutional research, and partnerships between industry and academia. Growing interest in personalized medical solutions is also supporting adoption. Progress in bio fabrication, expanding biotechnology and pharmaceutical industries, and government-backed research initiatives are creating favourable conditions for continued regional expansion.

Key players in the market

Some of the key players in 3D Bioprinting & Tissue Engineering Market include 3D Systems Inc., Advanced Solutions Life Sciences LLC, Aspect Biosystems Ltd., Cellbricks, Clecell, CollPlant Biotechnologies Ltd., CTIBIOTECH(TM), Cyfuse Biomedical K.K., Inventia Life Science Pty Ltd., GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH, Integra LifeSciences Corporation, Materialise, Organovo Holdings Inc., Poietis, RegenHU, Stratasys Ltd., TissueLabs and Regemat 3D.

Key Developments:

In August 2026, 3D Systems announced it has been awarded an additional $9 million under the Air Force-funded 'Large-Format Metal 3D Printer Advanced Technology Demonstrator' program. This award represents the next planned phase of the program 3D Systems has been executing since 2023, focused on the development and demonstration of large-scale, high-temperature, flight-relevant metal 3D printing technologies.

In January 2026, Aspect Biosystems and Novo Nordisk have commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes. The collaboration, which began in 2023, aims to create therapies that can replace, repair, or supplement biological functions in patients, advancing the development of disease-modifying treatments.

Technologies Covered:

  • Extrusion-based Bioprinting
  • Inkjet Bioprinting
  • Laser-assisted Bioprinting
  • Magnetic Bioprinting
  • Photopolymerization

Materials Covered:

  • Natural Biomaterials
  • Synthetic Biomaterials
  • Hybrid Biomaterials
  • Living Cells

Applications Covered:

  • Tissue Engineering
  • Organ Transplant & Regeneration
  • Drug Discovery & Development
  • Cosmetic & Reconstructive Surgery
  • Cancer Research Models

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Surgical Centers
  • Cosmetic Clinics

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global 3D Bioprinting & Tissue Engineering Market, By Technology

  • 5.1 Extrusion-based Bioprinting
  • 5.2 Inkjet Bioprinting
  • 5.3 Laser-assisted Bioprinting
  • 5.4 Magnetic Bioprinting
  • 5.5 Photopolymerization

6 Global 3D Bioprinting & Tissue Engineering Market, By Material

  • 6.1 Natural Biomaterials
  • 6.2 Synthetic Biomaterials
  • 6.3 Hybrid Biomaterials
  • 6.4 Living Cells

7 Global 3D Bioprinting & Tissue Engineering Market, By Application

  • 7.1 Tissue Engineering
  • 7.2 Organ Transplant & Regeneration
  • 7.3 Drug Discovery & Development
  • 7.4 Cosmetic & Reconstructive Surgery
  • 7.5 Cancer Research Models

8 Global 3D Bioprinting & Tissue Engineering Market, By End User

  • 8.1 Academic & Research Institutes
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Hospitals & Surgical Centers
  • 8.4 Cosmetic Clinics

9 Global 3D Bioprinting & Tissue Engineering Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 3D Systems Inc.
  • 12.2 Advanced Solutions Life Sciences LLC
  • 12.3 Aspect Biosystems Ltd.
  • 12.4 Cellbricks
  • 12.5 Clecell
  • 12.6 CollPlant Biotechnologies Ltd.
  • 12.7 CTIBIOTECH(TM)
  • 12.8 Cyfuse Biomedical K.K.
  • 12.9 Inventia Life Science Pty Ltd.
  • 12.10 GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
  • 12.11 Integra LifeSciences Corporation
  • 12.12 Materialise
  • 12.13 Organovo Holdings Inc.
  • 12.14 Poietis
  • 12.15 RegenHU
  • 12.16 Stratasys Ltd.
  • 12.17 TissueLabs
  • 12.18 Regemat 3D

List of Tables

  • Table 1 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Technology (2023-2034) ($MN)
  • Table 3 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Extrusion-based Bioprinting (2023-2034) ($MN)
  • Table 4 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Inkjet Bioprinting (2023-2034) ($MN)
  • Table 5 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Laser-assisted Bioprinting (2023-2034) ($MN)
  • Table 6 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Magnetic Bioprinting (2023-2034) ($MN)
  • Table 7 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Photopolymerization (2023-2034) ($MN)
  • Table 8 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Material (2023-2034) ($MN)
  • Table 9 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Natural Biomaterials (2023-2034) ($MN)
  • Table 10 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Synthetic Biomaterials (2023-2034) ($MN)
  • Table 11 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Hybrid Biomaterials (2023-2034) ($MN)
  • Table 12 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Living Cells (2023-2034) ($MN)
  • Table 13 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Application (2023-2034) ($MN)
  • Table 14 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 15 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Organ Transplant & Regeneration (2023-2034) ($MN)
  • Table 16 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 17 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Cosmetic & Reconstructive Surgery (2023-2034) ($MN)
  • Table 18 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Cancer Research Models (2023-2034) ($MN)
  • Table 19 Global 3D Bioprinting & Tissue Engineering Market Outlook, By End User (2023-2034) ($MN)
  • Table 20 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 21 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 22 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Hospitals & Surgical Centers (2023-2034) ($MN)
  • Table 23 Global 3D Bioprinting & Tissue Engineering Market Outlook, By Cosmetic Clinics (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.